Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients
Diana Posa(Centro de Investigaciones Biológicas Margarita Salas), Ángeles Martín‐Requero(Centro de Investigación Biomédica en Red), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Gracia Porras(Centro de Investigaciones Biológicas Margarita Salas), Siranjeevi Nagaraj(Université Libre de Bruxelles), Loreto Martínez‐González(Consejo Superior de Investigaciones Científicas), Fernando Benito Bartolomé(Biomedical Research Networking Center on Neurodegenerative Diseases)
Cited by 36
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293